Trexquant Investment LP Lowers Stake in Organon & Co. (NYSE:OGN)

Trexquant Investment LP lessened its holdings in Organon & Co. (NYSE:OGN) by 33.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 188,832 shares of the company’s stock after selling 93,795 shares during the period. Trexquant Investment LP owned approximately 0.07% of Organon & Co. worth $2,723,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Nordea Investment Management AB lifted its holdings in Organon & Co. by 2,016.0% in the 4th quarter. Nordea Investment Management AB now owns 3,128,810 shares of the company’s stock valued at $44,648,000 after purchasing an additional 2,980,945 shares in the last quarter. Invesco Ltd. raised its position in Organon & Co. by 23.7% in the third quarter. Invesco Ltd. now owns 10,240,630 shares of the company’s stock worth $177,777,000 after acquiring an additional 1,963,682 shares in the last quarter. Norges Bank purchased a new position in shares of Organon & Co. in the fourth quarter valued at $26,321,000. Sound Shore Management Inc. CT boosted its stake in Organon & Co. by 35.2% in the 4th quarter. Sound Shore Management Inc. CT now owns 4,675,137 shares of the company’s stock worth $67,415,000 after buying an additional 1,216,522 shares during the last quarter. Finally, Private Management Group Inc. lifted its stake in shares of Organon & Co. by 78.5% in the 4th quarter. Private Management Group Inc. now owns 2,335,238 shares of the company’s stock valued at $33,674,000 after purchasing an additional 1,027,276 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

OGN has been the topic of several analyst reports. The Goldman Sachs Group lifted their price objective on Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Piper Sandler upped their price target on Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, April 29th.

Organon & Co. Trading Down 1.7 %

Shares of NYSE:OGN traded down $0.36 during midday trading on Friday, hitting $20.99. The company had a trading volume of 1,043,753 shares, compared to its average volume of 2,196,285. The stock has a market cap of $5.40 billion, a price-to-earnings ratio of 5.13, a PEG ratio of 0.93 and a beta of 0.81. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $24.08. The company has a current ratio of 1.65, a quick ratio of 1.15 and a debt-to-equity ratio of 181.35. The firm has a fifty day simple moving average of $19.14 and a 200 day simple moving average of $16.41.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, May 2nd. The company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.83 by $0.31. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The company had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. On average, analysts predict that Organon & Co. will post 4.3 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Stockholders of record on Monday, May 13th will be given a dividend of $0.28 per share. The ex-dividend date is Friday, May 10th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.34%. Organon & Co.’s dividend payout ratio (DPR) is currently 27.38%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.